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The major histocompatibility complex (MHC) class II molecules are critical to
the generation of the immune response . These molecules consist of an a chain
of ^-34,000 Mr and a ,B chain of ^-25,000MT which are encoded by the MHC .
Helper T cells are known to recognize processed foreign antigen in the context
of this a(3 heterodimer . The ao heterodimer has been found to be associated
with several non-MHC-encoded molecules during its biosynthesis and/or expres-
sion, but the role of these molecules in the biology of the class II molecules is
largely unknown . In humans, several molecules have been described . These
molecules include the y, or invariant chain, and the related species 72, 7s , p41,
and p25 (1-5) . In addition, the as heterodimer has been shown to be associated
with a 40,000-70,000 M, chondroitin-4-sulfate proteoglycan molecule (6) .
Recent studies from our laboratory (7) in mice showed that the core protein
of the murine la-associated proteoglycan was the murine invariant chain, and
thus established the proteoglycan as an alternatively processed form of invariant
chain that was associated with class II molecules . In this report, we present data
indicating that the human invariant chain and some of its related components
are the core protein(s) ofthe human class II-associated proteoglycan . In addition,
we demonstrate that virtually all ofthe class II-associated proteoglycan is present
at the cell surface .
Materials and Methods
Cells .
￿
The DR5 homozygous cell line, Swei (HLA-A29, A29, B40, B40, DR5, DR5,
DRw52, DRw52, DQw3, DQw3) originally obtained fromJohn Hansen (Fred Hutchinson
Cancer Research Center, Seattle, WA) was used as the source of the proteoglycan in these
studies (8) . The Swei cells were maintained in RPMI 1640 containing 10% dialyzed FCS .
Antibodies . 1800D2.4 is a murine anti-DR monoclonal antibody produced in our
laboratory . Leu-10 is a murine anti-DQ antibody purchased from Becton, Dickenson &
Co ., (Mountain View, CA) (9) . VIC-Y1, a murine anti-human invariant chain antibody
has been described previously (5) . C351 is a rabbit antiserum produced against a synthetic
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peptide corresponding to the C-terminal region (residues 192-211) of human invariant
chain.' D 1 C 10 is an irrelevant murine monoclonal antibody used as a control. Rabbit
anti-mouse immunoglobulin (RaMIg)' was purchased from Accurate Chemical & Scien-
tific Corp. (Westbury, NY.)
Biosynthetic Labeling and Solubilization.
￿
Biosynthetic labeling with ['H]leucine, "SO.,,
[s5S]methionine, and ['H]methionine was done as previously described (6, 7). In brief,
cells were labeled at a density of 2 x 106 cells/ml for 5 h at 37°C in precursor-deficient
media containing 250-500,uCi of the appropriate radiolabeled precursor. After washing,
cells were solubilized either in PBS containing 0.5% NP-40 or in 0.05 M sodium acetate,
0.15 M NaCl, 0.5% Triton X-100, pH 6.0 (associative DEAE starting buffer), containing
protease inhibitors (6, 7). The cell lysates were ultracentrifuged at 100,000 g for 60 min
to remove insoluble debris.
Purification ofthe Class II-associated Proteoglycan.
￿
Under associative buffer conditions,
the associative DEAE-buffer lysate was applied in batch to the anion-exchange resin
DEAE-Sephacel (Pharmacia Inc ., Piscataway, NJ) at a ratio of 0.1 ml of packed Sephacel
per 108 cell equivalents. Unbound material was collected, and the DEAE-Sephacel was
washed with 0.2 M NaCI, 0.05 M sodium acetate, 0.5% Triton X-100, pH 6.0. Bound
material was eluted with 0.8 M NaCI, 0.05 M sodium acetate, 0.002% Triton X-100
(DEAE elution buffer). After elution, the eluate was adjusted to 0.2 M NaCI, pH 7 .4 .
Immunoprecipitation.
￿
Detergent iysates or DEAE-purified eluates were precleared (6,
7) and then reacted with monoclonal antibodies, or rabbit antiserum. Monoclonal anti-
body-antigen complexes were pelleted using protein A-Sepharose (Pharmacia, Inc.) which
had been prearmed with RaMIg (RaMIg-protein A). Rabbit antiserum-antigen com-
plexes were pelleted with protein A-Sepharose.
Purification of the Class II-associated Proteoglycan under Dissociative Conditions.
Antibody and radiolabeled molecules were eluted from the immunoprecipitates using
DEAE-associative starting buffer containing 8 M urea (DEAE-dissociative starting buffer),
and the eluates were applied batchwise to fresh DEAE-Sephacel. Unbound material was
collected, and the DEAE-Sephacel was washed in DEAE-dissociative buffer containing 0.2
M NaCl, Material bound to the DEAE-Sephacel was eluted with DEAE elution buffer.
Chondroitinase Treatment of the Class 11-associated Proteoglycan.
￿
The DEAE elution
buffer containing the doubly purified chondroitin sulfate proteoglycan (CSPG) was diluted
with three volumes of chondroitinase buffer (0.05 M Tris, pH 6.0, containing 0.01
BSA) and divided into two aliquots. One aliquot was treated with chondroitinase AC
(Miles Laboratories, Inc., Elkhart, IN) (1 .5 U/ml) to yield the core protein of the
proteoglycan, and the other was mock digested. In some experiments, chondroitinase
ABC (Miles Laboratories, Inc.) was used in place of chondroitinase AC. Samples were
incubated at 37'C for 2 h. The core protein or mock-digested proteoglycan was precipi-
tated by the addition of TCA to a final concentration of 20% (wt/vol).
SDS-PAGE.
￿
For analytical or preparative SDS-PAGE, immunoprecipitates were eluted
in or samples were adjusted to 0.062 M Tris, 2.0% SDS, 2% 2-ME, 10% glycerol, and
0.001% phenol red, and then boiled for 2 .5 min. Samples were electrophoresed through
a 1-cm 4% stacking gel and a 11 .5-cm 1 I % (except where indicated) running gel using a
modification of the Laemmli-Maizel system (10, 11). Gels were processed for autoradiog-
raphy.
Trypsin Digestion.
￿
The bands of interest in the SDS-PAGE slab gel were localized by
autoradiography. The pieces of gel containing the bands were excised, reswollen in 30%
methanol/10% acetic acid, washed in distilled water, and then placed in 0.5 ml of 0.1 M
NH4HCOs, pH 8 .2, containing 0 .1 ml of N-tosyl-t.-phenylalanine chloromethyl ketone
' O'Sullivan, D. M ., C. Wong, R. A. Houghten, and V. Quaranta. Identification of invariant
chain-related components in la oligomers by antipeptide antisera. Manuscript submitted for publi-
cation.
'Abbreviations used in this paper: CSPG, chondroitin-4-sulfate proteoglycan; NRS, normal rabbit
serum; RaMIg, rabbit anti-mouse immunoglobulin ; TPCK, N-tosyl-t.-phenylalanine chloromethyl
ketone.1424
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(TPCK)-trypsin (200 ug/ml) in 0.001 N HCl) (Worthington Biochemical Corp., Freehold,
NJ). The mixture was incubated for 30 min at 37 ° C, at which time 10 ul of 0.4 M
NH4HCO3, pH 8.2, and an additional 0 .1 ml of TPCK-trypsin was added, and the
incubation was continued overnight. The reaction was stopped by the addition of 0.1 ml
of 0.8 N acetic acid. The gel pieces were removed by centrifugation, and the eluates were
chromatographed on a C-18 reverse-phase column (Vydac, Hesperia, CA) using a gradient
(see Results) of 0-50% acetonitrile (J. T. Baker Chemical Co., Phillipsburg, NJ) in
trifluoroacetic acid (Pierce Chemical Co., Rockford, IL) and a HPLC system (Waters
Associates, Milford, MA).
Reprecipitation oftheCSPG andItsCore Protein.
￿
The mock-digested and chondroitinase-
treated doubly purified CSPG containing the CSPG and its core protein respectively were
each pretreated by immunoprecipitation with DIC10 and RaMIg-protein A. Aliquots of
the pretreated samples were reacted with DIC10, 1800D2.4, VIC-Y1, C351, or normal
rabbit serum (NRS), and immunoprecipitation was accomplished using RaMIg-protein
A, or protein A as appropriate. The immunoprecipitates were analyzed by SDS-PAGE
using a 1 I % running gel .
Two-dimensional Gel Electrophoresis.
￿
The mock-digested, doubly purified CSPG and
the chondroitinase-treated, doubly purified core protein were chromatographed on Seph-
adex G-25 in IEF elution buffer (8 M urea, 5% 2-ME, 2% ampholytes, pH 3.5-10, [LKB
Products, Gaithersburg, MD] and 0.1 % NP-40). The samples were then analyzed by two-
dimensional gel electrophoresis as previously described (6, 12).
Reaction ofAntibody with Intact Cells.
￿
Swei cells were labeled for 5 h with [3H]leucine
or
35S04. After labeling, viable cells were purified by centrifugation through Ficoll-
Hypaque, washed, and divided into two groups. One group of cells was incubated with
antibody for 30 min at 4°C, washed three times in PBS containing 1% dialyzed FCS at
4 ° C, and then solubilized in 0.5% NP-40 containing a fivefold excess of unlabeled Swei
cell extract. The unlabeled extract was added to block any available binding sites remaining
on the cell-bound antibodies. The second group of cells was solubilized immediately with
0 .5% NP-40, and aliquots of the detergent lysate were incubated with antibody for 30
min at 4° C. Antigen-antibody complexes were then isolated using RaMIg bound to
Staphylococcus aureus Cowan I strain. Immune complexes were dissociated with SDS and
were analyzed by SDS-PAGE.
Chondroitinase Treatment of Intact Cells.
￿
Swei cells were radiolabeled with 35504 or
[3H]leucine for 3 h, washed, and then resuspended in 0.15 M NaCl, 0.005 M Tris, pH
7 .4, containing 0.01% BSA and 0.02% sodium azide. The sodium azide was added to
diminish turnover and/or endocytosis of the CSPG (13). Chrondroitinase AC (1 .5 U/ml)
was added to half of each preparation, and the samples were incubated at 37°C for 30
min. The cells were washed three times in PBS. Cell viability was >98% as judged by
trypan blue exclusion. The cells were solubilized in PBS containing 0.5% NP-40. The
lysates were ultracentrifuged and pretreated, and immunoprecipitates were prepared and
analyzed by SDS-PAGE on 1 I % slab gels as described above.
Results
The strategy we used to characterize the core protein of the CSPG associated
with human class II molecules was adapted (Fig. 1) from the one successfully
employed in the murine system (7). In brief, [s5S]methionine-radiolabeled pro-
teoglycans and their associated molecules were purified from lysates of Swei cells
by their ability to be bound by DEAE-Sephacel. This first purification was
performed under associative conditions to maintain the a#y-CSPG complex as a
unit. Unbound material was collected, and then the DEAE-bound material that
contained the a,dy-CSPG complex was eluted with 0.8 M NaCI. After dilution,
the a#y-CSPG complex was isolated from other proteoglycans in the eluate by
specific immunoprecipitation with the murine anti-human invariant chain mono-
clonal antibody VIC-Y1 (5). The CSPG was then dissociated with other cotnpo-GIACOLETTO ET AL.
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FIGURE 1 .
￿
Strategy for characterization of the core protein,
nents in the complex by 8 M urea treatment, and purified by DEAE-Sephacel
chromatography under dissociative conditions to preclude its reassociation with
the a, a, or y chains. The unbound fraction containing these chains was collected
and the bound fraction containing the CSPG was again eluted by 0.8 M NaCl.
After dilution, the purified CSPG was treated with the chondroitin sulfate
glycosaminoglycan-specific glycosidase, chondroitinase AC, to generate the
CSPG core protein(s). The core proteins were purified by SDS-PAGE and
compared with the family of invariant chains by a number of biochemical and
immunochemical analyses.
Fig. 2 shows the SDS-PAGE analysis of the doubly purified [35S]methionine-
labeled CSPG before chondroitinase treatment (lane 4). The CSPG migrates as
a broad band with an Mr of 40,000-70,000. Particularly notable is the absence
of any bands corresponding to the a, ,Q, or y chains, similar to the finding in the
murine system (7). The doubly purified CSPG represents ^-19.5% of the radio-
activity immunoprecipitated from the associative DEAE-Sephacel-bound frac-
tion, 0.25% of the radioactivity in the associative DEAE-Sephacel-bound fraction1426
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FIGURE 2 .
￿
Isolation of the twice-purified CSPG core protein . Swei cells were labeled with
[s5S]methionine and solubilized in DEAE-associative starting buffer . The CSPG was purified
with class II molecules by associative anion-exchange chromatography and immunoprecipita-
tion using the anti-human invariant chain monoclonal antibody VIC-Y1, and then alone by
dissociative anion-exchange chromatography .An aliquot ofthe twice-purified CSPG wasmock
digested (("S]Methionine PG-CHase), and the remainder was treated with chondroitinase
(( 5S]Methionine + CHase) . Other Swei cells were labeled with [5H]methionine and solubilized
in NP-40, and the lysate reacted directly with VIC-Y1 (( SH]Methionine 1 ;) . All samples were
subjected to SDS-11%a PAGE . [s5S]Methionine-labeled anti-DR (lane 1) and VIC-Y1 (lane 2)
immunoprecipitates of the unbound associative fraction and a "SO,-labeled VIC-Y1 immu-
noprecipitate showing the CSPG (bracket) are shown for comparison . The mock-digested
[s5S]methionine-labeled CSPG (lane 4), the chondroitinase-digested [s 5S]methionine-labeled
CSPG core proteins (lane 5), andthe ['H]methionine-labeled invariant chain proteins (lane 6)
are shown. The arrows and arrowheads next to lanes 5 and 6 indicate the bands taken for
comparative tryptic peptide mapping. Abbreviation : CHase, chondroitinase .
itself, and 0.014% of the radioactivity in the whole cell lysate . This degree of
purification demonstrates the power of this simple three-step procedure .
The SDS-PAGE profile of the core protein (lane 5) obtained after chondroi-
tinase treatment of the CSPG differs dramatically from that of the CSPG . The
broad band in the M r 40,000-70,000 region of the gel is no longer seen,
demonstrating the efficacy of the chondroitinase treatment . Instead, a series of
lower-Mr . [s5S]methionine-labeled proteins are seen . The most intense of these
bands migrates with an M, of ^-38,000 (lane 5, arrow) . Less intensebands migrate
withMr of 46,000 and 28,000 (lane 5, arrowhead) . The finding of three protein
bands generated after chondroitinase digestion of the CSPG suggested that the
CSPG could have as many as three core proteins, or that the lower-Mr core
proteins were partial degradation products of the larger .
To determine in a preliminary fashion if the generated core protein compo-GIACOLETTO ET AL.
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nents had any relationship to the members of the family of invariant chain
components, an anti-invariant chain immunoprecipitate prepared from an NP-
40 lysate of [3H]methionine-labeled Swei cells was analyzed by SDS-PAGE in a
parallel lane (lane 6). A series of bands is again seen. The most intense band
migrates with an M,. of ^-31,000 (lane 6, arrow); less intense bands migrate with
M,. of ^-41,000 and 25,000 (lane 6, arrowhead) . These bands correspond to the
y,, p4l, and p25 members of the family of invariant chain-related proteins.
Although the CSPG core proteins (lane 5) were larger than the invariant chain
proteins (lane 6), their periodicity was similar, suggesting a possible relationship
between the two sets ofproteins.
This relationship was further explored by comparative two-dimensional gel
analysis ofthe CSPG, its core proteins, and the invariant chain proteins (Fig. 3).
The CSPG migrates as two major species (Fig. 3A), similar to the pattern seen
for the murine CSPG (14). The major component (bracket) was detected as a
vertical band of fairly homogeneous pI of ^"6.1, and Mr of ^-40,000-70,000.
The second major component (brace) is seen as a diagonal spot of more hetero-
geneouspI (^"4.2-5.0)andM, of^-50,000-60,000. A series oflight spots(arrows)
of pl 4.6-5.8 and M ^-38,000-40,000 is also observed. The intense high-M,
acidic spots have not been identified, but for the most part they are unaffected
bychondroitinase treatment (compare with Fig. 3B). Ofnote again is the absence
ofany detectable conventional invariant chaincomponents in this doubly purified
CSPG preparation.
The two-dimensional gel pattern ofthe core proteins (Fig. 3B) released from
the CSPG by chondroitinase treatment is quite distinct from that of the CSPG.
The two major components of the CSPG are no longer seen. The most intense
set ofspots corresponding to the core proteins (bracket) is seen in the 38,000 Mr
range ofthe gel, across a heterogeneous pI range (4.5-7.2). The most acidic of
these spots (arrows) correspond exactly to the series of light spots seen in the
two-dimensional gel analysis of the CSPG (Fig. 3A, arrows) but are now more
intense. A second set of spots (curly bracket) is seen in the 28,000 Mr range of
the gel. The most intense ofthese migrates in the pI range of4.0-5.0. No readily
discernible set ofcore proteins in the M, 46,000 range was seen.
Two-dimensional gel analysis of the anti-invariant chain immunoprecipitate
(Fig. 3 C) demonstrated the previously observed pattern (3, 5). Comparison of
the core proteins (B) with the invariant chain proteins showed that the 38,000
Mrset ofcore proteins (B, bracket) corresponded to the 31,000 Aset ofinvariant
chain proteins (Fig. 3 C, bracket), but migrated at a more acidic pl. The 28,000
M, set of core proteins (B, brace) shows little obvious correspondence to the
25,000 Mr set ofinvariant chain proteins (C, brace and arrowheads), and migrates
in a more acidic pI range.
Although thetwo-dimensional gel analysissuggested a possible correspondence
between the CSPG core proteins and invariant chain proteins, the results were
far from conclusive. We therefore compared these sets of proteins by double-
label tryptic peptide analysis. Pieces of gel containing the 38,000 M- species of
core protein (Fig. 2, lane 5, arrow) and the 31,000 M, species of invariant chain
(Fig. 2, lane 6, arrow) were excised, and combined. Similarly, pieces of gel
containing the 28,000 M,. species of core protein and the 25,000 M,. species of1428
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FIGURE 3 .
￿
Two-dimensional gel comparison of the CSPG, its core proteins, and invariant
chain proteins. Aliquots of the material analyzed in lanes 4, 5, and 6 by one-dimensional gel
electrophoresis were also analyzed by two-dimensional gel electrophoresis . The CSPG (A)
migrates as two major components (bracket and brace), and several minorcomponents (arrows).
After chondroitinase digestion (B), the two major components are no longer seen . Instead,
the core protein migrates as a series of spots of ^-38,000 M, (bracket), the most acidic of which
(arrows) correspond exactly to the four components (arrows) seen in A. In addition, a 28,000
Mr acidic core protein is seen (B, brace) . The invariant chain proteins (C) migrate as a major
series of spots of
￿
31,000A two 25,000 M, spots (arrowheads) and an acidic 25,000 M* spot
(brace) . The a and 0 chains coprecipitated with the invariant chain antibody are labeled .0
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￿
Comparative tr~ptic peptide maps of the CSPG core protein and invariant chain .
Gel pieces containing the [3Slmethionine-labeled CSPG core protein (dashed line) and the
corresponding ['Hlmethionine labeled conventional invariant chain species (solid line) were
excised from the slab gel shown in Fig . 1, and combined, and the proteins digested with
trypsin . The resulting tryptic peptides were chromatographed on a C-18 reverse-phase column
usinga gradient of 0-50% acetonitrile in 0.1% trifluoracetic acid (-------). (A) Comparison of
the 38,000 M, core protein and -y, (Fig. 1, arrows) . (B) Comparison of the 18,000 M, core
proteinandp25 (Fig . 1, arrowheads) .
invariant chain (Fig . 2, lanes 5 and 6, arrowheads) were excised and combined .
The two sets of samples were subjected to trypsin digestion, and the resultant
peptides were separated on a C-18 reverse-phase HPLC column using a gradient
of 0-50% acetonitrile in 0.1% trifluoroacetic acid . The elution profiles are
shown in Fig . 4. The analysis of the larger Mr proteins is shown in Fig . 4A . 9-
10 peptides are seen for each chain . Although there are some quantitative
differences, virtually all of the peptides coelute, indicating the nearly complete
structural identity of the major CSPG core protein and invariant chain . The
analysis of the smaller-M r set of proteins is seen in Fig. 4B . Again, nine peptides
are observed for each chain, and virtually all of the peptides coelute . These
results demonstrate the structural relatedness of these components . The Mr1430
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differences observed on one- and two-dimensional gels between the CSPG core
proteins and the invariant chain proteins are most likely attributable to residual
carbohydrate moieties on the core protein. Chondroitinase digestion of proteo-
glycans leaves at least the internal trisaccharide xylose-galactose-galactose on the
core protein.
Comparison of the profiles in Fig. 4A and B demonstrates correspondence of
the peptides ofp25 with those ofinvariant chain (solid lines) and ofthe peptides
of the 28,000 Mr core protein with those of the 38,000 Mr core protein (dashed
lines). These results indicate that in each case, the smaller-M,. species is clearly
related to the larger-M, species. It is unclear if the smaller species is a partial
degradation product of the larger, or is an alternatively processed form. In
addition, a peptide map ofp41 (data not shown) demonstrated its relatedness to
p25 and y,.
The experiments above demonstrated the structural relatedness of the core
protein(s) and invariant chain protein(s) . We next determined whether these
proteins were antigenically similar. A ["S]methionine-labeled, doubly purified
CSPG preparation was further purified by an additional passage over DEAE-
Sephacel under dissociative conditions to eliminate any possible contamination
ofthe CSPG preparation with conventional invariant chain. Aliquots ofa doubly
purified 35504-labeled CSPG preparation and the triply purified [35S]methionine-
labeled CSPG preparation were taken to test for reactivity with anti-invariant
chain antibody. Half ofthe [s5S]methionine-labeled preparation was treated with
chondroitinase to generate the core proteins. The samples were then subjected
to a pre-precipitation step with RaMIg-protein A to remove any radiolabeled
material which potentially could bind nonspecifically to the immunoprecipitates.
The sampleswere then divided intoaliquots andtested forreactivity with D1C10,
VIC-Y1, C351, and NRS. The results are shown in Figs. 5 and 6. The 35S04-
labeled CSPG (Fig. 5), the [35S]methionine labeled CSPG (Fig. 6A), and the
[355]methionine-labeled core proteins (Fig. 6B) were not isolated in the DIC10
or NRS immunoprecipitates, but were isolated with the VIC-Y1 and C351
anti-invariant chain reagents. These results indicated that the CSPG and its core
protein bore epitopes recognized by anti-invariant chain antibodies. Of note,
the VIC-Y1 antibody made against intact human invariant chain reacts far better
with the 38,000 M, core protein than with the 28,000 M, species (Fig. 6A, lane
VIC-YI). In contrast, the C351 and antibody made against the C-terminal region
synthetic peptide reacts with both the 38,000 and 28,000 Acore protein species
in proportion to their representation in the eluate. (Fig. 6A, lane 351). This
finding suggests that the 28,000 A species includes at least some of the amino
acid residues present in the synthetic peptide (residues 192-211), but either does
not have or does not efficiently present the epitope recognized by VIC-Y1.
The absence ofany conventional invariant chain in the [35S]methionine labeled
CSPG preparation is demonstrated in Fig. 6A, lane 1 (eluate) and is confirmed
by the two-dimensional gelanalysisofa doubly purified CSPGpreparation shown
in Fig. 3A. This finding indicates that the presence of the CSPG and its core
proteins in the anti-invariant chain immunoprecipitates in this reimmunoprecip-
itation experiment is attributable to a direct reaction ofthese molecules with theGIACOLETTO ET AL .
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FIGURE 5 . "S04-labeled CSPG can be reprecipitated with anti-invariant chain antibody .
Doubly purified "S04-labeled CSPG was prepared from Swei cells as described in Materials
and Methods . The "S04-labeled CSPG was precleared with RaMIg and protein A, and then
aliquots were reacted with DICIO, VICY1, C351, or NRS, and immunoprecipitated with
RaMIg-protein A or protein A.
antibody, and not to a possible association of these molecules with any invariant
chain that potentially could have been contaminating the triply purified samples .
The CSPG purified from class II immunoprecipitates prepared using VIC-Y1
and the CSPG purified from class II immunoprecipitates prepared using
1800D2.4 have superimposable one- and two-dimensional gelpatterns, indicating
their identity (data not shown) . For quantitative reasons, the [s5S]methionine-
labeled CSPG purified from the VIC-Y1 immunoprecipitate was used in the
preceding experiments . Identical results to those shown in Fig . 5 were obtained
with an "S04-labeled CSPG purified from an 1800D2.4 immunoprecipitate
(data not shown) . The results from the preceding experiments confirm the
structural and antigenic identity of the humanCSPG core protein and invariant
chain .
In order to gain insight into a potential role of the CSPG in the biology of the
class II molecules, we next addressed the question ofwhere in the cell the CSPG-
class II complex was located . Because of the known role of proteoglycans in
intercellular (15) and cell matrix (16) interactions, we first determined whether
the proteoglycan was associated with class II molecules at the cell surface. Intact
cells were radiolabeled with [sH]leucine or asS04 for 5 h . After washing, the
cells were divided into two aliquots. To detect cell surface class II molecules, one
aliquot was reacted directly with antibody for 30 min, and then lysed in PBS
containing 0.5% NP-40 and a fivefold excess of unlabeled cells to bind any free
remaining antibody sites . To detect total cellular class II molecules, the second
aliquot of cells was lysed in PBS containing 0.5% NP-40, processed in the usual1432
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FIGURE 6.
￿
[e5S]methionine-labeled CSPG and its core proteins can be reprecipitated with
anti-invariant chain antibody . Aliquots of a triply purified ["S]methionine-labeled CSPG (A)
and its core proteins (B) were used to test reprecipitation with anti-invariant antibodies. The
samples were precleared, and reacted with NRS, C351, YIC-Y1, and DIC10 . Immunoprecip-
itates were made with protein A-Sepharose alone or with protein A-Sepharose armed with
RaMIg . The bracket in A shows the area of the gel in which [s5S]methionine-labeled core
protein is found . The arrowheads in B indicate the 38,000 and 28,000 M, core proteins. The
gel patterns of the eluate after pretreatment and the pretreatment immunoprecipitate are
shown for comparison . Abbreviation : CHase, chondroitinase .
way, and then reacted with antibody . Immunoprecipitates were prepared using
RaMIg-SaCI, and analyzed by SDS-PAGE . The results are shown in Fig . 7 .
['H]leucine-labeled class II molecules (top) are detected both from the total cell
lysates (lane DR) and at the cell surface (lane DR). In addition, immunoprecipi-
tates prepared after reaction of the antibody with cell surface class II molecules
clearly contain "S04-labeled CSPG (Fig . 7, bottom, lane DR). In each case, more
material is immunoprecipitable from the cell lysates than from the cell surface.GIACOLETTO ET AL .
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FIGURE 7 .
￿
TheCSPG is associated with HLA class II molecules of the cell surface. Swei cells
were labeled with [9H]leucine (top) or s5S04 (bottom) . After labeling, immunoprecipitates were
prepared either from NP-40 lysates (left lanes) or by incubation of intact cells with antibody
for 30 min at 4°C prior to detergent solubilization (right lanes) using control (-) or DR
antibodies. The running gel is a 10% polyacrylamide gel .
These results indicate that the CSPG is at least in part associated with cell surface
class 11 molecules . Of note, similar results were obtained after only a 15-min
pulse label (no chase) of "S04 indicating that this association of s5SO4-labeled
CSPG with cell surface la is extremely rapid. However, these results do not
directly determine whether the CSPG itself is expressed at the cell surface .
To address this last question, cells were labeled with [sH]leucine or "S04 for
3 h, washed, and then divided into two aliquots . One aliquot of intact cells was
treated with chondroitinase AC to remove all cell surface proteoglycan, and the
second aliquot was mock digested . Cell viability after chondroitinase digestion
was>98% . After digestion, the cells were washed three times, and solubilized in1434
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FIGURE 8 .
￿
The class II-associated CSPG is on the cell surface . Swei cells were labeled with
35S04 (left lanes) or ['H]leucine (right lanes) and washed extensively. Samples of labeled intact
cells were divided in half and either digested with chondroitinase (+ CHase) or mock digested
(-CHase) . The cells were again washed extensively and solubilized with NP-40,and the lysates
reacted the control DIC10 (C) or 1800D2 .4 (anti-DR) monoclonal antibodies. The [sH]-
leucine-labeled a and ß chains are seen in both the chondroitinase-treated and mock-digested
samples . In contrast, the 35S04-labeled proteoglycan is seen only in the mock-digested samples .
The residual s5SO4-labeled band seen after chondroitinase treatment is the sulfated a chain .
PBS containing 0.5% NP-40. The processed lysates were reacted with D 1C10
and 1800D2.4 . The SDS-PAGE analysis of immunoprecipitates is shown in Fig .
8. Equal amounts of [3H]leucine-labeled DR molecules are precipitable from
both the chondroitinase- and mock-digested samples . In contrast, 35SO4-labeled
CSPG is present in the sample prepared from mock-digested intact cells, but
totally absent from the sample prepared from chondroitinase-treated intact cells.
The residual 35S04-labeled band seen after chondroitinase treatment is sulfated
a chain.3 These results indicate that virtually all the 35S04-labeled class
II-associated CSPG is accessible to chondroitinase, and therefore must be ex-
pressed on the cell surface .
One caveat in the above experiment is the possibility that even after extensive
washing, chondroitinase remained on the intact cells . Solubilization by NP-40
would then allow intracellular proteoglycans to be digested by the enzyme, and
any intracellular class II-associated CSPG would no longer be detectable . To
address this possibility, unlabeled intact Swei cells were either chondroitinase
treated or mock digested, and washed three times to remove the enzyme . An
equal number of 35SO4-labeled intact Swei cells was then added to each aliquot
of unlabeled cells, the mixtures were solubilized by NP-40 detergent, and
s Sant, A. J., M. Zacheis, T. Rumbarger, K. S . Giacoletto, and B . D. Schwartz . Human la aand ß
chains are sulfated . Manuscript submitted for publication .GIACOLETTO ET AL.
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incubated at 37'C for 30 min. Chondroitinase was added back to one aliquot of
the lysate of 38S04-labeled and mock-digested unlabeled cells, and the mixture
was incubated at 37°C for 30 min. The processed lysates were then reacted with
1800D2.4 or D1C10. Equal amounts of 35SO4-labeled CSPG were precipitated
from the lysates that contained the condroitinase-treated or mock-digested
unlabeled cells (data not shown) . In contrast, no 35S04-labeled material was
detected when chondroitinase had been added after solubilization. These results
indicate that chondroitinase is not being retained on the intact cells after washing,
and confirm the interpretation of the results of the previous experiment that
virtually all the class 11-associated CSPG is present on the cell surface.
Discussion
The experiments presented here indicate that the human invariant chain (1'i)
and itsrelated components are the core proteins ofthe human class 11-associated
CSPG. They thus establish that in humans, as in mice (7), the CSPG is an
alternatively processed form of variant chain. Further, the results indicate that
virtually all the class II-associated CSPG is present on the cell surface.
The purification method we used was modified from that used in the murine
system (7), and involved three steps: associative affinity chromatography, im-
munoprecipitation, and dissociative affinity chromatography. This procedure
resulted in a >7,000-fold purification of the class II-associated CSPG, based on
[35S]methionine radioactivity. Removal of the glycosaminoglycan yielded the
core proteins.
On one-dimensional gel analysis, three distinct core proteins were visualized.
These migrated with Mr of 46,000, 38,000, and 28,000, and had the same
periodicity as the p41, -y,, and p25 invariant chain proteins. Tryptic peptide
analysis confirmed the identity ofthe 38,000 Mr core protein and 'Y1, and ofthe
28,000 Mr core protein and p25. Although there was insufficient radioactivity
of the 46,000 Mr core protein to prove identity of the 46,000 Mr core protein
and p41 by tryptic peptide analysis, we believe that this is most likely the case.
In addition, the peptide maps indicated the relatedness of p41, 'Y1, and p25, and
of the 38,000 and 28,000 Mr core proteins. These results suggest at least two
possibilities for the finding of several core proteins. First, each invariant chain
species can be independently processed to a proteoglycan form. The individual
invariant chain species may be generated either from distinct transcripts of a
single invariant chain gene (17) or as the result of proteolytic degradation ofa
larger invariant chain species. Alternatively, only the larger forms of invariant
chain (i.e., 7,, 72, 73 and p41) may be processed to a proteoglycan form, and
then this proteoglycan is degraded to a smaller form of which the core protein
is 28,000 Mr. Our data do not allow us to distinguish between these possibilities.
However, either of these possibilities would account for the finding of two
distinct populations of class II-associated proteoglycan on two-dimensional gel
electrophoretograms.
Studies on other CSPG suggest that the attachment site of the chondroitin-
sulfate glycosaminoglycan is on a serine residue that is immediately succeeded
by a glycine residue (18). If this holds true for the class I1-associated CSPG, it
would place the attachment site for the glycosaminoglycan at serine 202, the1436
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only serine in the human invariant chain sequence followed by glycine. This
postulate would then suggest that each core protein bears only a single glycosa-
minoglycan, though the latter can vary in size. The cleavage of the 38,000 Mr
core protein to the 28,000 M, core protein ( and presumably y,, to p25) would
have to be either C-terminal to serine 202 or at the N terminus.
The derived amino acid sequence of invariant chain suggests it is a transmem-
brane protein with the C terminus on the outside of the cell (19, 20). The
attachment site at serine 202 would thus indicate the glycosaminoglycan is
exposed on the cell surface. Our experiments demonstrating that the class
II-associated CSPG present in intact cells is susceptible to chondroitinase diges-
tion prove this hypothesis. The result of this experiment wassomewhat surprising
to us, however, in that it demonstrated that virtually all the class II-associated
CSPG in the cell was exposed on the cell surface. This result suggests that the
addition of the glycosaminoglycan to the invariant chain core protein must occur
immediately prior to the transport of the CSPG to the plasma membrane. It also
indicates that at least this form of invariant chain is on the cell surface.
Although some previous reports (4, 21-23) have noted the inability to detect
invariant chain on the cell surface, other more recent reports (D. M. O'Sullivan,
unpublished data, and 24) have indicated that cell-surface invariant chain can be
detected. The ability to detect invariant chain on the cell surface undoubtedly
depends on the ability of the antibody used to recognize an available epitope. If
the CSPG is the only form of invariant chain present on the cell surface, the
availability of the epitope may also be influenced by the presence of the glycos-
aminoglycan.
The presence of the CSPG form of invariant chain on the cell surface with
class II molecules again raises questions regarding the function of the invariant
chain/CSPG in the biology of class II molecules. In a previous report (7), we
organized the potential functions of this molecule into three non-mutually
exclusive areas: biosynthesis/targeting, turnover/recycling, and participation in
class II-mediated intercellular events. The data in this and other recent reports
do not at this time allow differentiation among these possibilities, but lend some
support to each of them. Recent studies from one of our (25) and other (26)
laboratories have demonstrated that chloroquine and monensin treatment of
cells prevent the dissociation of the invariant chain from the a# heterodimer.
Thesedata were interpreted to suggest that a low pH processing step, presumably
in a trans Golgi vesicle is responsible for the dissociation of the invariant chain
from the a# heterodimer. Disruption of this step may therefore prevent the
presumed final step in transport of the a,# heterodimer to the membrane (D. M.
O'Sullivan, unpublished data, and 26). However, because these and other lyso-
somotropic agents also prevent the addition of glycosaminoglycan to core pro-
teins (27, 28, and S. Rosamond, unpublished observations), these data can also
be interpreted to suggest that inhibition of the conversion of the invariant chain
to its proteoglycan form prevents the dissociation of the invariant chain from
the a,# complex, and possibly therefore the transport of the a,# heterodimer to
the cell surface by the CSPG. If this latter interpretation is correct, it supports
the role of the CSPG in targeting newly synthesized class II molecules to the
plasma membrane. Additionally, if recycling of class 11 molecules is required forGIACOLETTO ET AL.
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antigen processing and/or presentation, the CSPG could function to target
recycled class II molecules back to the cell membrane . In this context, the
structural and possible functional parallels between the invariant chain/CSPG
and transferrin receptor have already been noted (7).
The third possibility, that the class II-associated CSPG may participate in
cellular interactions involving the immune response, receives support from the
precedent for such participation by proteoglycans in other systems (15, 16), and
from our finding that virtually all the class II-associated CSPG is on the cell
surface.
Transfection experiments are currently exploring the role of the invariant
chain/CSPG in the expression and function of the class II molecules. These
experiments may help differentiate among the potential roles of the invariant
chain/CSPG, and should determine if this role is obligatory or facilitating in the
biology of class II molecules.
Summary
The human class II-associated chondroitin sulfate proteoglycan (CSPG) was
analyzed biochemically and immunologically to determine a possible relationship
with the human invariant chain (-yi) and its related components. The CSPG was
purified by a three-step procedure involving associative ion-exchange chroma-
tography, immunoprecipitation, and dissociative ion-exchange chromatography .
Treatment of the CSPG with chondroitinase revealed core proteins of MT
46,000, 38,000, and 28,000, with the 38,000 species most highly represented.
Tryptic peptide analysis revealed identity of the peptides of the 38,000 Mr core
protein and 7,, and of the 28,000 Mr species and p25. The CSPG and its core
proteins were shown to react directly with the mouse anti-human invariant chain
monoclonal antibody VIC-Y1 and a rabbit antiserum produced against a synthetic
peptide corresponding to the C-terminal end of invariant chain. These results
demonstrate that the invariant chain is the core protein of the class II-associated
CSPG. In addition, virtually all the CSPG was shown to be present on the cell
surface.
The authors thank Ms. Pat Stewartand Ms. Jewel Aldridge for expert preparation of the
manuscript.
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